Table 1.
Patients’ characteristics
| Number of patients (%) | |
|---|---|
| Sex | |
| Male | 31 (44) |
| Female | 39 (56) |
| Median age (years) | 64 (range 21–85) |
| FAB classification | |
| M0 | 6 (9) |
| M1 | 14 (20) |
| M2 | 14 (20) |
| M3 | 5 (7) |
| M4 | 12 (17) |
| M5 | 9 (13) |
| M6 | 9 (13) |
| Not classified | 1 (1) |
| Unfavorable FAB | 15 (22) |
| WHO classification | |
| AML with recurrent genetic abnormalities | 37 (53) |
| AML with myelodysplasia-related changes | 12 (17) |
| Therapy-related myeloid neoplasms | 3 (4) |
| Myeloid neoplasms with germline predisposition | 0 (0) |
| AML, not otherwise specified | 18 (26) |
| Primary/secondary AML | |
| Primary | 52 (74) |
| Secondary | 18 (26) |
| Blood count | |
| WBC (G/L) | 61 (range 5–448) |
| Hb (g/dl) | 8 (range 4–13) |
| Plt (G/L) | 41 (range 6–243) |
| NCCN risk score distribution | |
| Favorable | 24 (34.5) |
| Intermediate | 24 (34.5) |
| Poor | 17 (24) |
| Not classified | 5 (7) |
| Complete response after induction therapy π | 27 (66) |
FAB, French-American-British; WBC, white blood count; Hb, hemoglobin; Plt, thrombocytes; NCCN, National Comprehensive Cancer Network
πonly patients receiving anthracycline-based induction therapy, response assessment on day 25–35 after induction (CR, CRi)